SynthesisScientific reports2016
Soy isoflavone consumption and colorectal cancer risk: a systematic review and meta-analysis.
Synthesis in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 5 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Dietary factors and colorectal cancer risk in Asian populations: a systematic review and meta-analysis of cohort studies.Cancer causes & control : CCC · 2025Pooled it
- Polyphenols in the Prevention and Treatment of Colorectal Cancer: A Systematic Review of Clinical Evidence.Nutrients · 2024Pooled it
- Soy Product Consumption and the Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.Nutrients · 2024Pooled it
- National and subnational incidence, mortality and associated factors of colorectal cancer in China: A systematic analysis and modelling study.Journal of global health · 2023Pooled it
- Meta-analysis of Soy Consumption and Gastrointestinal Cancer Risk.Scientific reports · 2017Pooled it
- Impact of 18-Month Soy Protein Supplementation on Steroid Hormones and Serum Biomarkers of Angiogenesis, Apoptosis, and the Growth Hormone/IGF-1 Axis: Results of a Randomized, Placebo-Controlled Trial in Males Following Prostatectomy.Nutrition and cancer · 2022Trial
- Association Between the Dietary Index for Gut Microbiota (DI-GM) and Colorectal Cancer in the PLCO Cohort.Nutrients · 2026Article
- Soybean Synergies: A Comprehensive Review on Novel Extraction Techniques and Their Role in Unlocking Health Potential.Food science & nutrition · 2025Review
- The use of Isoflavones as Lung Cancer Chemoprevention Agents and their Implications in Treatment through Radio Sensitization.Current medicinal chemistry · 2025Review
- Article
- Biological Properties ofAntioxidants (Basel, Switzerland) · 2024Article
- Equol: a metabolite of gut microbiota with potential antitumor effects.Gut pathogens · 2024Review
- Role of sex steroids in colorectal cancer: pathomechanisms and medical applications.American journal of cancer research · 2024Review
- Soy and Gastrointestinal Health: A Review.Nutrients · 2023Review
- Differential effects of various dietary proteins on dextran sulfate sodium-induced colitis in mice.Nutrition research and practice · 2022Article
- The Preparation of Gen-NHPharmaceutics · 2022Article
- A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer.Journal of biomedical science · 2022Article
- Enzymatic Metabolism of Flavonoids by Gut Microbiota and Its Impact on Gastrointestinal Cancer.Cancers · 2021Review
- Article
- Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans.Antioxidants (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most predominant solid carcinomas in Western countries. However, there is conflicting information on the effects of soy isoflavone on CRC risk. Therefore, we performed a meta-analysis to assess the association between soy isoflavone consumption and CRC risk in humans using PubMed, Embase, Web of Science, and Cochrane Library databases. A total of 17 epidemiologic studies, which consisted of thirteen case-control and four prospective cohort studies, met the inclusion criteria. Our research findings revealed that soy isoflavone consumption reduced CRC risk (relative risk, RR: 0.78, 95% CI: 0.72-0.85; I(2) = 34.1%, P = 0.024). Based on subgroup analyses, a significant protective effect was observed with soy foods/products (RR: 0.79; 95% CI: 0.69-0.89), in Asian populations (RR: 0.79; 95% CI: 0.72-0.87), and in case-control studies (RR: 0.76; 95% CI: 0.68-0.84). Therefore, soy isoflavone consumption was significantly associated with a reduced risk of CRC risk, particularly with soy foods/products, in Asian populations, and in case-control studies. However, due to the limited number of studies, other factors may affect this association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.